medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2017, Number 2

<< Back Next >>

Residente 2017; 12 (2)

Lupus eritematoso sistémico y su relación con el biomarcador alfa-klotho

Guzmán-Silahua S, Mendoza-Vázquez G, Aceves-Aceves JA, Nava-Zavala AH

Language: Spanish
References: 31
Page: 58-66
PDF size: 316.81 Kb.


ABSTRACT

Systemic lupus erythematosus (SLE) is an autoimmune pathology of unknown etiology in which the abnormal production of autoantibodies, the deposition of immune complexes, among other factors causes a wide range of manifestations and multiple complications. In the absence of a totally specific examination for this pathology different biomarkers are used as clinical and therapeutic support. Biomarkers can help predict the development of a disease since they have been associated with the activity, evolution and treatment of a certain disease. Since alfa-klotho (α-Kl) has been implicated in different processes including inflammation, the possibility of the α-KI fulfilling the role of a new potential biomarker in SLE is under consideration.


REFERENCES

  1. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008; 40 (2): 204-210.

  2. Rivas-Larrauri F, Yamazaki-Nakashimada MA. Systemic lupus erythematosus: Is it one disease? Reumatol Clin. 2016; 12 (5): 274-281.

  3. Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012; 64 (2): 159-168.

  4. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016; 12 (10): 605-620.

  5. Cervera R, Pallarés L. Capítulo 2. Epidemiología y clasificación del lupus eritematoso sistémico. En: Cervera R, Jiménez-Alonso J. Avances en lupus eritematoso sistémico. Barcelona: Marge Medica Books; 2008: pp. 9-22.

  6. Sánchez-Díaz MR, Nucamendi-Cervantes GC et al. ¿Qué es el Lupus eritematoso? Boletín Epidemiológico del sistema Nacional de Vigilancia, Sistema único Informativo. México: 2013; 1-28.

  7. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25 (11): 1271-1277.

  8. Molina-Restrepo JF. El laboratorio en las enfermedades reumáticas autoinmunes. Medicina & Laboratorio. 2007; 13 (01-02): 11-33.

  9. Crispín JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med. 2010; 16 (2): 47-57.

  10. Munoz LE, Gaipl US, Franz S, Sheriff A, Voll RE, Kalden JR et al. SLE--a disease of clearance deficiency? Rheumatology (Oxford). 2005; 44 (9): 1101-1107.

  11. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390 (6655): 45-51.

  12. Jawiarczyk-Przybyłowska A, Halupczok-Żyła J, Bolanowski M. Soluble α-Klotho - a new marker of acromegaly? Endokrynol Pol. 2016; 67 (4): 390-396.

  13. Kureya Y, Kanazawa H, Ijiri N, Tochino Y, Watanabe T, Asai K et al. Down-regulation of soluble α-klotho is associated with reduction in serum irisin levels in chronic obstructive pulmonary disease. Lung. 2016; 194 (3): 345-351.

  14. Hori S, Miyake M, Onishi S, Tatsumi Y, Morizawa Y, Nakai Y et al. Clinical significance of α‑ and β‑Klotho in urothelial carcinoma of the bladder. Oncol Rep. 2016; 36 (4): 2117-2125.

  15. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P et al. Suppression of aging in mice by the hormone Klotho. Science. 2005; 309 (5742): 1829-1833.

  16. Maeda R, Imura A, Nabeshima Y. Complex regulation and diverse functions of alpha-klotho. Contrib Nephrol. 2013; 180: 25-46.

  17. Nabeshima Y. Discovery of alpha-Klotho unveiled new insights into calcium and phosphate homeostasis. Proc Jpn Acad Ser B Phys Biol Sci. 2009; 85 (3): 125-141.

  18. Oswiecimska JM, Pys-Spychala M, Swietochowska E, Ostrowska Z, Szymlak A, Mikolajczak A, Malczyk Z, Chyra M. Serum alpha-klotho concentrations in girls with anorexia nervosa. Neuro Endocrinol Lett. 2015 Dec; 36(6):539-44.

  19. Siahanidou T, Garatzioti M, Lazaropoulou C, Kourlaba G, Papassotiriou I, Kino T et al. Plasma soluble α-klotho protein levels in premature and term neonates: correlations with growth and metabolic parameters. Eur J Endocrinol. 2012; 167 (3): 433-440.

  20. Drew DA, Katz R, Kritchevsky S, Ix J, Shlipak M, Gutiérrez OM et al. Association between soluble klotho and change in kidney function: the health aging and body composition study. J Am Soc Nephrol. 2017; 28 (6): 1859-1866.

  21. Neyra JA, Hu MC. αklotho and chronic kidney disease. Vitam Horm. 2016; 101: 257-310.

  22. Ushigusa T, Ichinose K, Sato S, Michitsuji T, Shimizu T, Umeda M et al. Soluble α-klotho is a potential biomarker associated with neuropsychiatric systemic lupus erythematosus. Clin Immunol. 2016; 165: 29-34.

  23. Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, Aono Y et al. Establishment of sandwich ELISA for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun. 2010; 398 (3): 513-518.

  24. Neidert MC, Sze L, Zwimpfer C, Sarnthein J, Seifert B, Frei K et al. Soluble α-klotho: a novel serum biomarker for the activity of GH-producing pituitary adenomas. Eur J Endocrinol. 2013; 168 (4): 575-583.

  25. Akimoto T, Kimura T, Watanabe Y, Ishikawa N, Iwazu Y, Saito O et al. The impact of nephrectomy and renal transplantation on serum levels of soluble Klotho protein. Transplant Proc. 2013; 45 (1): 134-136.

  26. Pavlatou MG, Remaley AT, Gold PW. Klotho: a humeral mediator in CSF and plasma that influences longevity and susceptibility to multiple complex disorders, including depression. Transl Psychiatry. 2016; 6 (8): e876.

  27. Hu MC, Shi M, Zhang J, Quiñones H, Kuro-o M, Moe OW. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int. 2010; 78 (12): 1240-1251.

  28. Sugiura H, Yoshida T, Mitobe M, Yoshida S, Shiohira S, Nitta K et al. Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrol Dial Transplant. 2010; 25 (1): 60-68.

  29. Semba RD, Cappola AR, Sun K, Bandinelli S, Dalal M, Crasto C et al. Plasma klotho and cardiovascular disease in adults. J Am Geriatr Soc. 2011; 59 (9): 1596-1601.

  30. Navarro-González JF, Donate-Correa J, Muros de Fuentes M, Pérez-Hernández H, Martínez-Sanz R, Mora-Fernández C. Reduced Klotho is associated with the presence and severity of coronary artery disease. Heart. 2014; 100 (1): 34-40.

  31. Prystupa A, Dąbrowska A, Sak JJ, Tarach J, Toruń-Jurkowska A, Lachowska-Kotowska P et al. Concentrations of fetuin-A, osteoprotegerin and α-Klotho in patients with alcoholic liver cirrhosis. Exp Ther Med. 2016; 12 (5): 3464-3470.




2020     |     www.medigraphic.com